Listed

Neumora Therapeutics, Inc.

NMRANasdaqCIK 1885522HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$42.2m, Q2 FY2026
Net income−$43.1m, Q2 FY2026
Neumora Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m41.6Research and development, Q3 FY2023, three months to 2023-09-30$41.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0000950170-24-125437.Report this figure38.9Research and development, Q4 FY2023, three months to 2023-12-31$38.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-03, accession 0000950170-25-030401. Derived: 12-month figure less the 9-month figure.Report this figure45.8Research and development, Q1 FY2024, three months to 2024-03-31$45.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-12, accession 0000950170-25-069311.Report this figure48.6Research and development, Q2 FY2024, three months to 2024-06-30$48.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-06, accession 0000950170-25-104138.Report this figure60.6Research and development, Q3 FY2024, three months to 2024-09-30$60.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure45.9Research and development, Q4 FY2024, three months to 2024-12-31$45.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001193125-26-130388. Derived: 12-month figure less the 9-month figure.Report this figure52.2Research and development, Q1 FY2025, three months to 2025-03-31$52.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure38.7Research and development, Q2 FY2025, three months to 2025-06-30$38.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure40.5Research and development, Q3 FY2025, three months to 2025-09-30$40.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure44.7Research and development, Q4 FY2025, three months to 2025-12-31$44.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001193125-26-130388. Derived: 12-month figure less the 9-month figure.Report this figure38.6Research and development, Q1 FY2026, three months to 2026-03-31$38.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure29.3Research and development, Q2 FY2026, three months to 2026-06-30$29.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure
Operating income$m(56.9)Operating income, Q3 FY2023, three months to 2023-09-30−$56.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0000950170-24-125437.Report this figure(114)Operating income, Q4 FY2023, three months to 2023-12-31−$114.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-03, accession 0000950170-25-030401. Derived: 12-month figure less the 9-month figure.Report this figure(60.1)Operating income, Q1 FY2024, three months to 2024-03-31−$60.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0000950170-25-069311.Report this figure(63.8)Operating income, Q2 FY2024, three months to 2024-06-30−$63.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-06, accession 0000950170-25-104138.Report this figure(76.6)Operating income, Q3 FY2024, three months to 2024-09-30−$76.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure(62.9)Operating income, Q4 FY2024, three months to 2024-12-31−$62.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001193125-26-130388. Derived: 12-month figure less the 9-month figure.Report this figure(70.9)Operating income, Q1 FY2025, three months to 2025-03-31−$70.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure(54.0)Operating income, Q2 FY2025, three months to 2025-06-30−$54.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure(57.7)Operating income, Q3 FY2025, three months to 2025-09-30−$57.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure(58.5)Operating income, Q4 FY2025, three months to 2025-12-31−$58.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001193125-26-130388. Derived: 12-month figure less the 9-month figure.Report this figure(52.9)Operating income, Q1 FY2026, three months to 2026-03-31−$52.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure(42.2)Operating income, Q2 FY2026, three months to 2026-06-30−$42.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure
Interest expense$mnot reportednot reportednot reportednot reported0.0Interest expense, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure0.0Interest expense, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-30, accession 0001193125-26-130388. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure0.3Interest expense, Q2 FY2025, three months to 2025-06-30$307.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure0.7Interest expense, Q3 FY2025, three months to 2025-09-30$747.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure0.8Interest expense, Q4 FY2025, three months to 2025-12-31$827.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2026-03-30, accession 0001193125-26-130388. Derived: 12-month figure less the 9-month figure.Report this figure1.4Interest expense, Q1 FY2026, three months to 2026-03-31$1.4m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure1.4Interest expense, Q2 FY2026, three months to 2026-06-30$1.4m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure
Income tax$mnot reportednot reportednot reported0.1Income tax, Q2 FY2024, three months to 2024-06-30$125.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-06, accession 0000950170-25-104138.Report this figure0.1Income tax, Q3 FY2024, three months to 2024-09-30$53.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-30, accession 0001193125-26-130388. Derived: 12-month figure less the 9-month figure.Report this figure0.1Income tax, Q1 FY2025, three months to 2025-03-31$105.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$25.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-30, accession 0001193125-26-130388. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$30.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure
Net income$m(53.0)Net income, Q3 FY2023, three months to 2023-09-30−$53.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0000950170-24-125437.Report this figure(109)Net income, Q4 FY2023, three months to 2023-12-31−$108.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-03, accession 0000950170-25-030401. Derived: 12-month figure less the 9-month figure.Report this figure(53.7)Net income, Q1 FY2024, three months to 2024-03-31−$53.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure(58.7)Net income, Q2 FY2024, three months to 2024-06-30−$58.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure(72.5)Net income, Q3 FY2024, three months to 2024-09-30−$72.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure(58.8)Net income, Q4 FY2024, three months to 2024-12-31−$58.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001193125-26-130388. Derived: 12-month figure less the 9-month figure.Report this figure(68.0)Net income, Q1 FY2025, three months to 2025-03-31−$68.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure(52.7)Net income, Q2 FY2025, three months to 2025-06-30−$52.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure(56.8)Net income, Q3 FY2025, three months to 2025-09-30−$56.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure(59.5)Net income, Q4 FY2025, three months to 2025-12-31−$59.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001193125-26-130388. Derived: 12-month figure less the 9-month figure.Report this figure(53.5)Net income, Q1 FY2026, three months to 2026-03-31−$53.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure(43.1)Net income, Q2 FY2026, three months to 2026-06-30−$43.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure
Diluted EPS$ per share(1.14)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$1.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0000950170-24-125437.Report this figurenot reported(0.34)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0000950170-25-069311.Report this figure(0.37)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-06, accession 0000950170-25-104138.Report this figure(0.45)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figurenot reported(0.42)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.42 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure(0.33)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure(0.35)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figurenot reported(0.30)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure(0.23)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure
Basic EPS$ per share(1.14)Basic EPS, Q3 FY2023, three months to 2023-09-30−$1.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0000950170-24-125437.Report this figurenot reported(0.34)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0000950170-25-069311.Report this figure(0.37)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-06, accession 0000950170-25-104138.Report this figure(0.45)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figurenot reported(0.42)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.42 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure(0.33)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.33 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure(0.35)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figurenot reported(0.30)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.30 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure(0.23)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.23 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure

Balance sheet

Cash and equivalents$116.8m, Q2 FY2026
Long-term debt$52.9m, Q2 FY2026
Shareholders' equity$44.5m, Q2 FY2026
Neumora Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m412Cash and equivalents, Q3 FY2023, at 2023-09-30$412.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0000950170-24-125437.Report this figure374Cash and equivalents, FY2023, at 2023-12-31$374.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-03, accession 0000950170-25-030401.Report this figure183Cash and equivalents, Q1 FY2024, at 2024-03-31$182.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0000950170-25-069311.Report this figure151Cash and equivalents, Q2 FY2024, at 2024-06-30$150.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-06, accession 0000950170-25-104138.Report this figure276Cash and equivalents, Q3 FY2024, at 2024-09-30$275.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure142Cash and equivalents, FY2024, at 2024-12-31$142.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-30, accession 0001193125-26-130388.Report this figure127Cash and equivalents, Q1 FY2025, at 2025-03-31$126.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure125Cash and equivalents, Q2 FY2025, at 2025-06-30$124.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-06, accession 0000950170-25-104138.Report this figure129Cash and equivalents, Q3 FY2025, at 2025-09-30$129.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure183Cash and equivalents, FY2025, at 2025-12-31$182.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure147Cash and equivalents, Q1 FY2026, at 2026-03-31$147.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure117Cash and equivalents, Q2 FY2026, at 2026-06-30$116.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure
Current assets$m526Current assets, Q3 FY2023, at 2023-09-30$525.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-01, accession 0000950170-23-057424.Report this figure478Current assets, FY2023, at 2023-12-31$478.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-03, accession 0000950170-25-030401.Report this figure443Current assets, Q1 FY2024, at 2024-03-31$442.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0000950170-24-054448.Report this figure398Current assets, Q2 FY2024, at 2024-06-30$398.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-06, accession 0000950170-24-091737.Report this figure349Current assets, Q3 FY2024, at 2024-09-30$348.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0000950170-24-125437.Report this figure314Current assets, FY2024, at 2024-12-31$314.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-30, accession 0001193125-26-130388.Report this figure255Current assets, Q1 FY2025, at 2025-03-31$254.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0000950170-25-069311.Report this figure223Current assets, Q2 FY2025, at 2025-06-30$222.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-06, accession 0000950170-25-104138.Report this figure177Current assets, Q3 FY2025, at 2025-09-30$177.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure191Current assets, FY2025, at 2025-12-31$190.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure153Current assets, Q1 FY2026, at 2026-03-31$153.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure125Current assets, Q2 FY2026, at 2026-06-30$124.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure
Total assets$m545Total assets, Q3 FY2023, at 2023-09-30$544.7m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-01, accession 0000950170-23-057424.Report this figure496Total assets, FY2023, at 2023-12-31$496.2m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-03, accession 0000950170-25-030401.Report this figure450Total assets, Q1 FY2024, at 2024-03-31$450.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0000950170-24-054448.Report this figure404Total assets, Q2 FY2024, at 2024-06-30$404.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-06, accession 0000950170-24-091737.Report this figure353Total assets, Q3 FY2024, at 2024-09-30$352.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0000950170-24-125437.Report this figure317Total assets, FY2024, at 2024-12-31$317.0m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-30, accession 0001193125-26-130388.Report this figure257Total assets, Q1 FY2025, at 2025-03-31$256.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0000950170-25-069311.Report this figure224Total assets, Q2 FY2025, at 2025-06-30$223.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-06, accession 0000950170-25-104138.Report this figure178Total assets, Q3 FY2025, at 2025-09-30$177.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure191Total assets, FY2025, at 2025-12-31$191.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure154Total assets, Q1 FY2026, at 2026-03-31$153.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure125Total assets, Q2 FY2026, at 2026-06-30$125.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure
Current liabilities$m29.1Current liabilities, Q3 FY2023, at 2023-09-30$29.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-01, accession 0000950170-23-057424.Report this figure25.1Current liabilities, FY2023, at 2023-12-31$25.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-03, accession 0000950170-25-030401.Report this figure24.6Current liabilities, Q1 FY2024, at 2024-03-31$24.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0000950170-24-054448.Report this figure23.1Current liabilities, Q2 FY2024, at 2024-06-30$23.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-06, accession 0000950170-24-091737.Report this figure31.7Current liabilities, Q3 FY2024, at 2024-09-30$31.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0000950170-24-125437.Report this figure29.9Current liabilities, FY2024, at 2024-12-31$29.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-30, accession 0001193125-26-130388.Report this figure28.4Current liabilities, Q1 FY2025, at 2025-03-31$28.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0000950170-25-069311.Report this figure21.2Current liabilities, Q2 FY2025, at 2025-06-30$21.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-06, accession 0000950170-25-104138.Report this figure25.8Current liabilities, Q3 FY2025, at 2025-09-30$25.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure32.5Current liabilities, FY2025, at 2025-12-31$32.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure30.1Current liabilities, Q1 FY2026, at 2026-03-31$30.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure27.8Current liabilities, Q2 FY2026, at 2026-06-30$27.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure
Total liabilities$m32.1Total liabilities, Q3 FY2023, at 2023-09-30$32.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-01, accession 0000950170-23-057424.Report this figure27.1Total liabilities, FY2023, at 2023-12-31$27.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-03, accession 0000950170-25-030401.Report this figure25.7Total liabilities, Q1 FY2024, at 2024-03-31$25.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-07, accession 0000950170-24-054448.Report this figure23.2Total liabilities, Q2 FY2024, at 2024-06-30$23.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-06, accession 0000950170-24-091737.Report this figure31.8Total liabilities, Q3 FY2024, at 2024-09-30$31.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0000950170-24-125437.Report this figure29.9Total liabilities, FY2024, at 2024-12-31$29.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-30, accession 0001193125-26-130388.Report this figure28.4Total liabilities, Q1 FY2025, at 2025-03-31$28.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-12, accession 0000950170-25-069311.Report this figure40.9Total liabilities, Q2 FY2025, at 2025-06-30$40.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-06, accession 0000950170-25-104138.Report this figure45.7Total liabilities, Q3 FY2025, at 2025-09-30$45.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure87.2Total liabilities, FY2025, at 2025-12-31$87.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure83.2Total liabilities, Q1 FY2026, at 2026-03-31$83.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure80.7Total liabilities, Q2 FY2026, at 2026-06-30$80.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reported0.0Long-term debt, FY2024, at 2024-12-31$0. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figurenot reported19.5Long-term debt, Q2 FY2025, at 2025-06-30$19.5m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-08-06, accession 0000950170-25-104138.Report this figure19.6Long-term debt, Q3 FY2025, at 2025-09-30$19.6m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure54.5Long-term debt, FY2025, at 2025-12-31$54.5m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure53.0Long-term debt, Q1 FY2026, at 2026-03-31$53.0m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure52.9Long-term debt, Q2 FY2026, at 2026-06-30$52.9m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reported20.0Current portion of debt, Q2 FY2025, at 2025-06-30$20.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2025-08-06, accession 0000950170-25-104138.Report this figure20.0Current portion of debt, Q3 FY2025, at 2025-09-30$20.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure60.0Current portion of debt, FY2025, at 2025-12-31$60.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2026-03-30, accession 0001193125-26-130388.Report this figure60.0Current portion of debt, Q1 FY2026, at 2026-03-31$60.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure60.0Current portion of debt, Q2 FY2026, at 2026-06-30$60.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure
Shareholders' equity$m513Shareholders' equity, Q3 FY2023, at 2023-09-30$512.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0000950170-24-125437.Report this figure469Shareholders' equity, FY2023, at 2023-12-31$469.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-30, accession 0001193125-26-130388.Report this figure425Shareholders' equity, Q1 FY2024, at 2024-03-31$424.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure381Shareholders' equity, Q2 FY2024, at 2024-06-30$381.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure321Shareholders' equity, Q3 FY2024, at 2024-09-30$320.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure287Shareholders' equity, FY2024, at 2024-12-31$287.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure228Shareholders' equity, Q1 FY2025, at 2025-03-31$228.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure183Shareholders' equity, Q2 FY2025, at 2025-06-30$182.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure132Shareholders' equity, Q3 FY2025, at 2025-09-30$132.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure104Shareholders' equity, FY2025, at 2025-12-31$103.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure70.7Shareholders' equity, Q1 FY2026, at 2026-03-31$70.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure44.5Shareholders' equity, Q2 FY2026, at 2026-06-30$44.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure

Cash flow

Operating cash flow−$39.5m, Q2 FY2026
Capital expenditure$44.0k, Q4 FY2023
Neumora Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(47.8)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$47.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0000950170-24-125437. Derived: 9-month figure less the 6-month figure.Report this figure(51.4)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$51.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-03, accession 0000950170-25-030401. Derived: 12-month figure less the 9-month figure.Report this figure(43.0)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$43.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0000950170-25-069311.Report this figure(56.2)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$56.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-06, accession 0000950170-25-104138. Derived: 6-month figure less the 3-month figure.Report this figure(33.5)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$33.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269446. Derived: 9-month figure less the 6-month figure.Report this figure(50.3)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$50.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001193125-26-130388. Derived: 12-month figure less the 9-month figure.Report this figure(59.4)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$59.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure(52.4)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$52.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001193125-26-350370. Derived: 6-month figure less the 3-month figure.Report this figure(46.6)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$46.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269446. Derived: 9-month figure less the 6-month figure.Report this figure(48.0)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$48.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001193125-26-130388. Derived: 12-month figure less the 9-month figure.Report this figure(46.4)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$46.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure(39.5)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$39.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001193125-26-350370. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$37.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-12, accession 0000950170-24-125437. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$44.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-03, accession 0000950170-25-030401. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)185.16m, Q2 FY2026
Neumora Therapeutics, Inc., shares, quarterly
Line itemUnitperiod not labelled2022-09-30period not labelled2023-03-31period not labelled2023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares27.6Diluted shares (weighted), period not labelled, three months to 2022-09-3027,646,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-01, accession 0000950170-23-057424.Report this figure29.3Diluted shares (weighted), period not labelled, three months to 2023-03-3129,277,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0000950170-24-054448.Report this figure30.1Diluted shares (weighted), period not labelled, three months to 2023-06-3030,125,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-06, accession 0000950170-24-091737.Report this figure46.7Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3046,691,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0000950170-24-125437.Report this figure158Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31157,943,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0000950170-25-069311.Report this figure159Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30158,984,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-06, accession 0000950170-25-104138.Report this figure160Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30159,576,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure161Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31161,451,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure162Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30161,691,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure162Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30161,838,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269446.Report this figure180Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31179,872,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001193125-26-211825.Report this figure185Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30185,163,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure

Shares outstanding: 187.90mShares outstanding, period not labelled, at 2026-08-10187,895,912 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001193125-26-350370.Report this figure at Aug 10, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.